Possibia

2178709

Last Update Posted: 2022-04-19

Recruiting has ended

All Genders

accepted

18 Years +

48 Estimated Participants

No Expanded Access

Interventional Study

Does not accept healthy volunteers

A Phase II Study of Neoadjuvant FOLFIRINOX

The primary objective of this study is to evaluate the rate of pathologic complete response to neoadjuvant FOLFIRINOX in patients with resectable pancreatic cancer using a tissue collection component.

Eligibility

Relevant conditions:

Resectable Pancreatic Ductal Adenocarcinoma

If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.

locations

Contact Information

Overall Contact

No valid contacts available

Data sourced from ClinicalTrials.gov